The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity
Abstract
Studies show that administration of interferon (IFN)-alpha causes a significant increase in depressive symptoms. The enzyme indoleamine 2,3-dioxygenase (IDO), which converts tryptophan (TRP) into kynurenine (KYN) and which is stimulated by proinflammatory cytokines, may be implicated in the development of IFN-alpha-induced depressive symptoms, first by decreasing the TRP availability to the brain and second by the induction of the KYN pathway resulting in the production of neurotoxic metabolites. Sixteen patients with chronic hepatitis C, free of psychiatric disorders and eligible for IFN-alpha treatment, were recruited. Depressive symptoms were measured using the Montgomery Asberg Depression Rating Scale (MADRS). Measurements of TRP, amino acids competing with TRP for entrance through the blood-brain barrier, KYN and kynurenic acid (KA), a neuroprotective metabolite, were performed using high-performance liquid chromatography. All assessments were carried out at baseline and 1, 2, 4, 8, 12 and 24 weeks after treatment was initiated. The MADRS score significantly increased during IFN-alpha treatment as did the KYN/TRP ratio, reflecting IDO activity, and the KYN/KA ratio, reflecting the neurotoxic challenge. The TRP/CAA (competing amino acids) ratio, reflecting TRP availability to the brain, did not significantly change during treatment. Total MADRS score was significantly associated over time with the KYN/KA ratio, but not with the TRP/CAA ratio. Although no support was found that IDO decreases TRP availability to the brain, this study does support a role for IDO activity in the pathophysiology of IFN-alpha-induced depressive symptoms, through its induction of neurotoxic KYN metabolites.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cytokine-induced activation of the enzyme, indolamine 2,3 dioxygenase (IDO), which metabolizes tryptophan to kynurenine and quinolinic acid, is believed to contribute to reduced availability of serotonin.16,23,24”
From Cytokines and Glucocorticoid Receptor Signaling (2009) · cites this paper as [24]
In the citing paper
“Following IDO activation, both the reduced peripheral availability of tryptophan (putatively leading to reduced serotonin synthesis in the brain) and the production of neurotoxic tryptophan metabolites are considered essential steps in the pathophysiological processes.”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“3-hydroxykynurenine and quinolinic acid are NMDA receptor agonists, potentially neurotoxic and thus potentially contributing to depression”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“which converts tryptophan into kynurenine (KYN), a precursor of 3-hydroxykynurenine, a neurotoxic metabolite, and kynurenic acid, a neuroprotective metabolite”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“kynurenic acid is an N-methyl d-aspartate (NMDA) receptor antagonist, and is generally considered neuroprotective”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Sheline, Y. I., Sanghavi, M., Mintun, M. A., & Gado, M. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05034.1999 · Cited by 1,382
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Research works printed but not linked: 2
- Maes M, Meltzer H . The serotonin hypothesis of major depression. In: Bloom F, Kupfer D, (eds) Psychopharmacology. Raven Press: New York, 1995 pp 933–944.
- Stockmeier CA, Mahajan G, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY et al. Neuronal and glial density is increased and neuronal soma size is decreased in the hippocampus in major depressive disorder (MDD). Biol Psychiatry 2003; 53S: 198.
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
O'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002148 · Cited by 1,278
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
“It should be noted that in addition to depletion of TRP, the generation of KYN also appears to have important effects on neurotransmitter function and behavior (Wichers et al., 2005).”
BackgroundMaes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
“Based on those results, a shift in the serotonin hypothesis of depression from serotonin depletion to inflammation-induced tryptophan and serotonin depletion with subsequent enhanced neurodegeneration by neurotoxic TRYCATs has been proposed (Wichers and Maes 2004; Wichers et al. 2005, 2007).”
BackgroundSelf-citation
Metadata
- Authors
- Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M.
- Affiliations
- Maastricht University (NL)
- Maastricht University Medical Centre (NL)
- Ziekenhuis Oost-Limburg (BE)
- University of Antwerp (BE)
- Corresponding author
- Wichers, M C
- Venue
- Molecular Psychiatry
- Published
- 2004-10-19
- Volume
- 10
- Issue
- 6
- Pages
- 538-544
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2078660110
- Cited by
- 445
- References
- 54
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 17 · 2023: 17 · 2022: 15 · 2021: 28 · 2020: 23 · 2019: 17 · 2018: 31 · 2017: 20 · 2016: 30 · 2015: 24 · 2014: 17 · 2013: 26 · 2012: 28
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- indoleamine 2,3-dioxygenase, interferon-alpha, depressive symptoms, tryptophan depletion, kynurenine pathway, kynurenic acid, neurotoxicity, chronic hepatitis C, blood-brain barrier, tryptophan availability, inflammatory cytokines
- MeSH terms
- Adult, Depression, Female, Follow-Up Studies, Humans, Immunotherapy, Kynurenic Acid, Kynurenine, Male, Middle Aged, Psychiatric Status Rating Scales, Tryptophan, Interferon-alpha, Hepatitis C, Chronic, Dioxygenases, Indoleamine-Pyrrole 2,3,-Dioxygenase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. https://app.cochat.ai/papers/10.1038/sj.mp.4001600
- The paper
- Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M. (2005). IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Molecular Psychiatry. https://doi.org/10.1038/sj.mp.4001600
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.